drugset / Trial / NCT07209475

Effect of Amnio-Maxx on the Healing Rate of Chronic Diabetic Foot Ulcers.

NCT07209475 ↗

Phase 4 Recruiting 248 enrolled Royal Biologics
RandomizedParallel-groupOpen-labelTreatment

Summary

This study will evaluate a cellular, acellular, matrix-like product (CAMP) and Standard of Care (SOC) versus SOC alone in the closure of nonhealing diabetic foot ulcers (DFUs). The study will evaluate Amnio-Maxx® Dual Layer Amnion Patch.

Timeline

Start
2025-08-14
Primary completion
2026-08-14
Completion
2026-08-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Amnio-Maxx® Dual Layer Amnion Patch Unknown — Other

Indications